Just a moment, the page is loading...

To initiate a Research Proposal or to Ask a Question about studies, please do the following:

  • Login and create an account.
  • Click on the Study ID to view Study Details.
  • If you cannot find the specific study you are looking for, click here to submit an Enquiry
×


3021 Results:


Sponsor Studies ↑ Description Created
 
Astellas *ASTELLAS-9463-EC-0002 An Exploratory Study to Compare the Efficacy and Safety of Micafungin as a Pre-emptive Treatment of Invasive Candidiasis Versus Placebo in High Risk Surgical Subjects with Intra-abdominal Infections - A Multicentre, Randomized, Double-blind Study 7/31/2017
 
Bayer *BAYER-15786 A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS). 4/18/2019
 
Eisai *EISAI-E2007-J000-335 A Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures 11/30/2018
 
Eisai *EISAI-E2080-G000-303 A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome 11/30/2018
 
Eisai *EISAI-E7080-G000-201 Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology 11/30/2018
 
Eisai *EISAI-E7080-G000-205 Ph1b An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment 11/30/2018
 
Eisai *EISAI-E7080-G000-205 Ph2 An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment 11/30/2018
 
Eisai *EISAI-E7080-G000-303 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer 11/30/2018
 
Eisai *EISAI-E7080-G000-304 A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma 11/30/2018
 
Eisai *EISAI-E7080-J081-103 An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors 11/30/2018